Cutaneous adverse events and gemifloxacin: observations from the clinical trial program

Area of Science:

• Pharmacology
• Dermatology
• Infectious Diseases

Background:

• Cutaneous adverse events are common with antimicrobial use.
• Gemifloxacin showed a signal for rash in early research.
• Further analysis revealed a mild, self-limiting rash mainly with prolonged use (>7 days).

Purpose of the Study:

• To review extensive studies on gemifloxacin's safety profile.
• To support the use of gemifloxacin for short-term community infections.
• To characterize the incidence and nature of gemifloxacin-associated rash.

Main Methods:

• Review of clinical research data and subsequent analyses.
• Evaluation of rash incidence based on duration of gemifloxacin exposure.
• Assessment of potential links to sensitization and severe cutaneous reactions.

Main Results:

• Rash incidence is <1.5% with 5-day gemifloxacin use for community-acquired respiratory tract infections.
• Rash is mild-moderate, self-limited, and macular-papular.
• No association found with cross-sensitization, subclinical sensitization, Stevens-Johnson Syndrome, or Toxic Epidermal Necrolysis.

Conclusions:

• Short-term gemifloxacin (5 days) for community infections has a low rash rate (<1.5%).
• The observed rash is generally mild, self-limiting, and similar to other fluoroquinolones.
• Gemifloxacin's safety profile supports its use for indicated short durations, with no evidence of severe dermatologic sequelae.